TherapeuticsMD Inc (NASDAQ:TXMD) CEO Robert G. Finizio sold 184,000 shares of TherapeuticsMD stock in a transaction that occurred on Friday, September 21st. The stock was sold at an average price of $6.63, for a total transaction of $1,219,920.00. Following the transaction, the chief executive officer now directly owns 18,485,559 shares in the company, valued at approximately $122,559,256.17. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.
Shares of NASDAQ:TXMD traded up $0.08 during mid-day trading on Monday, reaching $6.70. The company had a trading volume of 2,161,300 shares, compared to its average volume of 2,496,695. The company has a current ratio of 7.88, a quick ratio of 7.79 and a debt-to-equity ratio of 0.94. The stock has a market capitalization of $1.53 billion, a PE ratio of -17.97 and a beta of 1.54. TherapeuticsMD Inc has a one year low of $4.34 and a one year high of $7.66.
TherapeuticsMD (NASDAQ:TXMD) last posted its quarterly earnings results on Monday, July 30th. The company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.03). The company had revenue of $3.80 million during the quarter, compared to the consensus estimate of $4.23 million. TherapeuticsMD had a negative return on equity of 80.75% and a negative net margin of 582.86%. The company’s revenue for the quarter was down 11.6% compared to the same quarter last year. During the same period last year, the firm posted ($0.10) EPS. research analysts predict that TherapeuticsMD Inc will post -0.63 earnings per share for the current year.
Several equities analysts have commented on TXMD shares. Oppenheimer set a $12.00 target price on shares of TherapeuticsMD and gave the stock a “buy” rating in a research report on Wednesday, May 30th. ValuEngine cut shares of TherapeuticsMD from a “buy” rating to a “hold” rating in a report on Friday, June 1st. BidaskClub raised shares of TherapeuticsMD from a “sell” rating to a “hold” rating in a report on Friday, June 8th. JPMorgan Chase & Co. began coverage on shares of TherapeuticsMD in a report on Friday, June 15th. They issued an “overweight” rating and a $11.00 price target on the stock. Finally, Cantor Fitzgerald set a $26.00 price target on shares of TherapeuticsMD and gave the stock a “buy” rating in a report on Monday, July 30th. Two equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $15.33.
TherapeuticsMD, Inc operates as a women's health care product company. Its pipeline of hormone therapy drug candidates include TX-001HR, a combination of estradiol and progesterone drug candidate under clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause; TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil; and TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy in post-menopausal women with vaginal linings that do not receive enough estrogen.
Recommended Story: How to Invest in an Index Fund
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.